ReviewNature reviews. Urology2020
Multiparametric MRI for prostate cancer diagnosis: current status and future directions.
Review in Nature reviews. Urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 227 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
227 citing papers in PubMed, 9 syntheses or guidelines pooled it, 374 citations in OpenAlex.
- Micro-ultrasonography- vs MRI-targeted biopsy in prostate cancer: Updated systematic review and meta-analysis.BJU international · 2026Pooled it
- The Role of Artificial Intelligence in the Characterization and Outcome Prediction of Prostate Cancer: A Systematic Review.Tomography (Ann Arbor, Mich.) · 2026Pooled it
- Machine learning-based MRI imaging for prostate cancer diagnosis: systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2026Pooled it
- Pooled it
- 10 mm (PI-RADS v2.1) versus 15 mm (PI-RADS v1.0) tumor capsule contact length in predicting extracapsular extension in prostate cancer: Meta-analysis and systematic review.Abdominal radiology (New York) · 2025Pooled it
- Dynamic behavior of the nucleus pulposus within the intervertebral disc loading: a systematic review and meta-analysis exploring the concept of dynamic disc model.Frontiers in bioengineering and biotechnology · 2025Pooled it
- AI-accelerated prostate MRI: a systematic review.The British journal of radiology · 2024Pooled it
- Head-to-head comparison of prostate-specific membrane antigen PET and multiparametric MRI in the diagnosis of pretreatment patients with prostate cancer: a meta-analysis.European radiology · 2024Pooled it
- Pooled it
- [Feasibility and clinical value of a prostate cancer screening model based on biparametric magnetic resonance imaging combined with prostate-specific antigen in a Chinese population].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Trial
- Incremental Impact of [Molecular imaging and biology · 2022Trial
- Recent advances in discriminating prostate cancer from benign prostatic diseases in the pre-biopsy population.Medical oncology (Northwood, London, England) · 2026Review
- Impact of prostate mpMRI quality on diagnostic accuracy in prostate cancer: a prospective study.BJU international · 2026Article
- An Assessment of PI-RADS v2.1: Inter-Reader Agreement, Diagnostic Accuracy, and the Added Value of PSA Density in Prostate Cancer Prediction.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- 5 T versus 3 T MRI for prostate cancer: an intra-individual prospective comparison of image quality and diagnostic performance.Prostate cancer and prostatic diseases · 2026Article
- MR Virtual Cytometry for Zone-specific Prostate Cancer Characterization with Histologic and Molecular Validation.Radiology. Imaging cancer · 2026Article
- PSMA PET: the answer to MRI-occult prostate cancer… or another mirage?European radiology · 2026Review
- Apparent diffusion coefficient radiomics for differentiating benign and malignant PI-RADS 3-5 prostate lesions: external validation.International urology and nephrology · 2026Article
- AI-Assisted Tumor Boundary Delineation via Targeted Ultrasmall Iron Oxide Nanoprobe for High-Contrast HER2-Positive Tumor Imaging.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
167 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 4 countries.
Funding
Abstract
The current diagnostic pathway for prostate cancer has resulted in overdiagnosis and consequent overtreatment as well as underdiagnosis and missed diagnoses in many men. Multiparametric MRI (mpMRI) of the prostate has been identified as a test that could mitigate these diagnostic errors. The performance of mpMRI can vary depending on the population being studied, the execution of the MRI itself, the experience of the radiologist, whether additional biomarkers are considered and whether mpMRI-targeted biopsy is carried out alone or in addition to systematic biopsy. A number of challenges to implementation remain, such as ensuring high-quality execution and reporting of mpMRI and ensuring that this diagnostic pathway is cost-effective. Nevertheless, emerging clinical trial data support the adoption of this technology as part of the standard of care for the diagnosis of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.